Key result
ErbB2 inhibition by AG-825 decreases cardiomyocyte disarray in an HCM mouse model.
Why the study?
While alterations in serine/threonine phosphorylation characterize heart failure, the contribution of tyrosine phosphorylation to the pathogenesis of cardiac hypertrophy remains unclear.
p-value: p=0.0014
Altered tyrosine phosphorylation, particularly involving the EGFR1 pathway, plays a regulatory role in hypertrophic cardiomyopathy, and pharmacological inhibition of ErbB2 can reduce cardiomyocyte disarray in a mouse model.
ErbB2 inhibition warrants exploration in human hypertrophic cardiomyopathy; this preclinical finding leaves open clinical translation.
Alterations of serine/threonine phosphorylation of the cardiac proteome are a hallmark of heart failure. However, the contribution of tyrosine phosphorylation (pTyr) to the pathogenesis of cardiac hypertrophy remains unclear. We use global mapping to discover and quantify site-specific pTyr in two cardiac hypertrophic mouse models, i.e., cardiac overexpression of ErbB2 (TgErbB2) and α myosin heavy chain R403Q (R403Q-αMyHC Tg), compared to control hearts. From this, there are significant phosphoproteomic alterations in TgErbB2 mice in right ventricular cardiomyopathy, hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM) pathways. On the other hand, R403Q-αMyHC Tg mice indicated that the EGFR1 pathway is central for cardiac hypertrophy, along with angiopoietin, ErbB, growth hormone, and chemokine signaling pathways activation. Surprisingly, most myofilament proteins have downregulation of pTyr rather than upregulation. Kinase-substrate enrichment analysis (KSEA) shows a marked downregulation of MAPK pathway activity downstream of k-Ras in TgErbB2 mice and activation of EGFR, focal adhesion, PDGFR, and actin cytoskeleton pathways. In vivo ErbB2 inhibition by AG-825 decreases cardiomyocyte disarray. Serine/threonine and tyrosine phosphoproteome confirm the above-described pathways and the effectiveness of AG-825 Treatment. Thus, altered pTyr may play a regulatory role in cardiac hypertrophic models.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2022) studied Hypertrophic cardiomyopathy. AG-825 vs. DMSO vehicle was evaluated on Cardiomyocyte disarray (circular variance) (p=0.0014). In vivo ErbB2 inhibition by AG-825 significantly decreased cardiomyocyte disarray in the TgErbB2 mouse model of hypertrophic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: